Trial Profile

An Alzheimer's disease tolerability and dosing trial of Alpha-1062

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 26 Aug 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Benzgalantamine (Primary)
Indications Alzheimer's disease
Focus Therapeutic Use
Acronyms Resolve
Sponsors AlphaCognition

Most Recent Events

25 Aug 2022 According to an Alpha Cognition media release, the Company has completed significant start-up activities in preparation to initiate the RESOLVE tolerability study to date. The Company is seeking additional capital to fund this study initiation and will commence the study within a quarter to securing the required funding.
31 May 2022 According to an Alpha Cognition media release, the company met with FDA during the second quarter of 2022 and received feedback regarding labeling and manufacturing. site initiation activities are underway with enrollment expected to commence early Q3, 2022.
03 May 2022 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com